TerrAscend (TSNDF) Income from Continuing Operations (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Income from Continuing Operations of 6829000.0 for Q1 2026, up 10.91% year-over-year from 6157426.77 in Q1 2025, and down 1233.79% quarter-over-quarter from 512000.0 in Q4 2025.
TerrAscend (TSNDF) Income from Continuing Operations (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Income from Continuing Operations for 6 consecutive years, with 6829000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 10.91% year-over-year to 6829000.0; the TTM figure through Mar 2026 stood at 23654000.0 (down 352.69% YoY), while the FY2025 annual figure was 24489000.0, down 412.76% from the prior year.
- Income from Continuing Operations slipped to 6829000.0 in Q1 2026 per TSNDF's latest filing, from 512000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 39147000.0 in Q4 2024 and bottomed at 300561000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 21773117.65 across 5 years, with a median of 7665000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 638.3% — and 2024, when it soared 1410.88%.
- TerrAscend's Income from Continuing Operations stood at 5666000.0 in 2022, then soared by 145.73% to 2591000.0 in 2023, then jumped by 1410.88% to 39147000.0 in 2024, then tumbled by 101.31% to 512000.0 in 2025, then plunged by 1233.79% to 6829000.0 in 2026.
- Business Quant data shows TSNDF's Income from Continuing Operations at 6829000.0 in Q1 2026, 512000.0 in Q4 2025, and 9907000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | TerrAscend | 187.17 Mn | 145.05 Mn | 36.25 Mn | -10.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.06 Mn |
| Mar 31, 2026 | -6.83 Mn |
| Dec 31, 2025 | -512,000.00 |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -7.67 Mn |
| Dec 31, 2024 | 39.15 Mn |
| Sep 30, 2024 | -15.84 Mn |
| Jun 30, 2024 | -6.29 Mn |
| Mar 31, 2024 | -14.85 Mn |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | -8.44 Mn |
| Jun 30, 2023 | -12.86 Mn |
| Mar 31, 2023 | -19.18 Mn |
| Dec 31, 2022 | -5.67 Mn |
| Sep 30, 2022 | -300.56 Mn |
| Jun 30, 2022 | 16.86 Mn |
| Mar 31, 2022 | -13.75 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 55.84 Mn |